Abstract
Lung cancer is one of the major cancer-related causes of death in developed countries. Especially squamous cell lung cancer (SCC) patients have scarce therapeutic options. We recently reported fibroblast growth factor receptor-type 1 (FGFR1) amplification to be associated with therapeutically tractable FGFR1 dependency in SCC. This makes FGFR1 a novel target for directed therapy in SCC.
Full Text
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call